An agent that improves survival in metastatic breast cancer patients has been launched. Herceptin (trastuzumab), a humanised monoclonal antibody, suppresses tumour growth in the 20-30 per cent of metastatic breast cancer patients who overproduce a growth factor called HER2. It binds HER2 receptors on the cancer cell surface so that ...